Invesco Portfolio holdings
Invesco Ltd., founded in 1978 and headquartered in Atlanta, Georgia, is a global investment management firm managing hundreds of billions in assets across a diverse range of products, including mutual funds, exchange-traded funds (ETFs), and institutional portfolios. Known for its blend of active and passive investment strategies, Invesco serves individual investors, financial advisors, and institutions, with a strong presence in North America, Europe, and Asia, bolstered by acquisitions like OppenheimerFunds in 2019. The firm offers specialized solutions in equities, fixed income, real estate, and alternatives, leveraging its global research capabilities to cater to varying market needs. Invesco’s commitment to innovation and client-focused investing has solidified its reputation as a versatile player in the asset management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$1.26B |
| 2 |
Salesforce
CRM
|
+$742M |
| 3 |
Flutter Entertainment
FLUT
|
+$607M |
| 4 |
iShares Core MSCI Emerging Markets ETF
IEMG
|
+$604M |
| 5 |
Amazon
AMZN
|
+$528M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$1.56B |
| 2 |
MRO
Marathon Oil Corporation
MRO
|
+$738M |
| 3 |
Alibaba
BABA
|
+$365M |
| 4 |
Vistra
VST
|
+$315M |
| 5 |
Philip Morris
PM
|
+$258M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.43% |
| 2 | Financials | 12.86% |
| 3 | Industrials | 11.55% |
| 4 | Consumer Discretionary | 10.57% |
| 5 | Healthcare | 9.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3626
Harvard Bioscience
HBIO
$28.8M
| $36.7K | ﹤0.01% |
1,740
+128
| +8% | +$2.94K |
|
|
FLNA
3627
Filana Therapeutics
FLNA
$48.2M
| $36.4K | ﹤0.01% |
15,408
-290,882
| -95% | -$5.11M |
|
|
SBDS
3628
DELISTED
Solo Brands Inc
SBDS
| $34.6K | ﹤0.01% |
758
+52
| +7% | +$2.58K |
|
3629
Acumen Pharmaceuticals
ABOS
$176M
| $34.1K | ﹤0.01% |
19,842
+1,653
| +9% | +$3.98K |
|
|
ADAP
3630
DELISTED
Adaptimmune Therapeutics
ADAP
| $34.1K | ﹤0.01% |
63,335
+28,526
| +82% | +$20.8K |
|
3631
AbCellera Biologics
ABCL
$2.85B
| $33K | ﹤0.01% |
11,253
+303
| +3% | +$844 |
|
3632
Verrica Pharmaceuticals
VRCA
$88M
| $31.6K | ﹤0.01% |
+4,513
| New | +$49.6K |
|
3633
ProQR Therapeutics
PRQR
$255M
| $31.5K | ﹤0.01% |
+11,887
| New | +$37.7K |
|
3634
GrowGeneration
GRWG
$85.9M
| $31.2K | ﹤0.01% |
18,485
+2,133
| +13% | +$4.08K |
|
3635
Lineage Cell Therapeutics
LCTX
$286M
| $31K | ﹤0.01% |
61,785
+1,272
| +2% | +$934 |
|
3636
Cabaletta Bio
CABA
$457M
| $30.6K | ﹤0.01% |
13,494
-371
| -3% | -$1.3K |
|
3637
Mammoth Energy Services
TUSK
$162M
| $30.4K | ﹤0.01% |
+10,122
| New | +$37.3K |
|
|
NOTE
3638
DELISTED
FiscalNote
NOTE
| $30.2K | ﹤0.01% |
2,354
+43
| +2% | +$524 |
|
3639
Nautilus Biotechnolgy
NAUT
$110M
| $30K | ﹤0.01% |
17,881
-2,739
| -13% | -$6.55K |
|
3640
Nkarta
NKTX
$176M
| $29.9K | ﹤0.01% |
+11,997
| New | +$37K |
|
3641
Aclaris Therapeutics
ACRS
$867M
| $27.8K | ﹤0.01% |
+11,215
| New | +$27.9K |
|
3642
Ovid Therapeutics
OVID
$489M
| $25.4K | ﹤0.01% |
27,207
-2,130
| -7% | -$2.38K |
|
3643
FibroBiologics
FBLG
$6.53M
| $25.3K | ﹤0.01% |
633
+12
| +2% | +$644 |
|
3644
Traeger
COOK
$172M
| $24.4K | ﹤0.01% |
+204
| New | +$31.3K |
|
|
LNAI
3645
Lunai Bioworks
LNAI
$10.7M
| $24.3K | ﹤0.01% |
363
+78
| +27% | +$5.18K |
|
3646
Shattuck Labs
STTK
$682M
| $22.7K | ﹤0.01% |
18,726
+337
| +2% | +$417 |
|
3647
Inovio Pharmaceuticals
INO
$76.1M
| $22K | ﹤0.01% |
12,037
+1,024
| +9% | +$4.53K |
|
3648
Werewolf Therapeutics
HOWL
$18.6M
| $21.6K | ﹤0.01% |
14,589
+953
| +7% | +$1.94K |
|
|
EQC
3649
DELISTED
Equity Commonwealth
EQC
| $19.2K | ﹤0.01% |
10,870
-229,094
| -95% | -$3.53M |
|
3650
Tenaya Therapeutics
TNYA
$165M
| $18.4K | ﹤0.01% |
12,876
+1,704
| +15% | +$3.82K |
|
Similar funds
Invesco's Q4 2024 Portfolio in Review
As of Q4 2024, Invesco held 3,867 positions worth $541B, up 4.4% from $518B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
Invesco deployed $18.6B of net new capital in Q4 2024, opening 126 new positions and adding to 2,143 existing holdings. Its largest new stake was Flutter Entertainment: 2,405,415 shares worth $622M.
By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 25% a quarter earlier, followed by Financials and Industrials.
On the sell side, the largest reduction was Broadcom, an estimated $1.56B trimmed.
- Invesco's largest Q4 2024 buy was Flutter Entertainment: 2,405,415 shares worth $622M.
- Invesco added most to NVIDIA in Q4 2024, an estimated $1.26B increase.
- Invesco's biggest Q4 2024 reduction was Broadcom, cutting an estimated $1.56B.
- Invesco fully exited Marathon Oil Corporation in Q4 2024, selling an estimated $738M.
- Invesco's ten largest holdings make up 19% of its $541B portfolio in Q4 2024.
- Invesco opened 126 new positions and closed 111 in Q4 2024.
- Invesco's portfolio value rose 4.4% quarter-over-quarter to $541B.
Based on Invesco's 13F filing for Q4 2024, filed 13 Feb 2025.